Search

Your search keyword '"Neelakantan, Pratap"' showing total 20 results
Start Over Author "Neelakantan, Pratap" Publication Year Range Last 10 years
20 results on '"Neelakantan, Pratap"'

1. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

Author

Salisbury, Richard A., Curto-Garcia, Natalia, O’Sullivan, Jennifer, Chen, Frederick, Polzella, Paolo, Godfrey, Anna L., Russell, James, Knapper, Steven, Willan, John, Frewin, Rebecca, Joshi, Shivani, Arami, Siamak, Burns, Sarah, Teh, Chun Huat, Wadelin, Frances, Dhanapal, Jaymathi, Neelakantan, Pratap, Milojkovic, Dragana, Psaila, Beth, Szydlo, Richard, Francis, Sebastian, Cargo, Catherine, Jain, Manish, McGregor, Andrew, Wallis, Louise, Duncombe, Andrew, Hussein, Hayder, Dyer, Peter, Munro, Laura, Bond, Lee, McMullin, Mary Frances, Somervaille, Tim C. P., Garg, Mamta, Sekhar, Mallika, Harrison, Claire, Mead, Adam J., and Innes, Andrew J.

Published
2021
Full Text
View/download PDF

2. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

Author

McLornan, Donal P., Godfrey, Anna L., Green, Anna, Frewin, Rebecca, Arami, Siamak, Brady, Jessica, Butt, Nauman M., Cargo, Catherine, Ewing, Joanne, Francis, Sebastian, Garg, Mamta, Harrison, Claire, Innes, Andrew, Khan, Alesia, Knapper, Steve, Lambert, Jonathan, Mead, Adam, McGregor, Andrew, Neelakantan, Pratap, and Psaila, Bethan

Subjects
MYELOFIBROSIS, HEMATOLOGY, DIAGNOSIS, PROGNOSIS, MEDICAL personnel, HEMATOPOIETIC stem cell transplantation
Abstract

This document is an update of the British Society for Haematology (BSH) guideline on myelofibrosis (MF), providing healthcare professionals with clear guidance on the diagnosis and prognostic evaluation of different types of MF. It emphasizes the importance of bone marrow biopsy and molecular testing for diagnosis, as well as the use of various prognostic models to inform clinical decisions and guide therapy. The document also discusses risk stratification and prognostication for MF patients, including the use of validated risk scores. Additionally, it provides information on the diagnosis and prognostication of prefibrotic MF, highlighting the importance of diagnostic criteria and mutational profiles. [Extracted from the article]

Published
2024
Full Text
View/download PDF

4. sj-docx-2-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Author

Mead, Adam J., Butt, Nauman M., Nagi, Waseem, Whiteway, Alastair, Kirkpatrick, Suriya, Rinaldi, Ciro, Roughley, Catherine, Ackroyd, Sam, Ewing, Joanne, Neelakantan, Pratap, Garg, Mamta, Tucker, David, Murphy, John, Patel, Hitesh, Bains, Rozinder, Chiu, Gavin, Hickey, Joe, Harrison, Claire, and Somervaille, Tim C. P.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-2-tah-10.1177_20406207221084487 for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study by Adam J. Mead, Nauman M. Butt, Waseem Nagi, Alastair Whiteway, Suriya Kirkpatrick, Ciro Rinaldi, Catherine Roughley, Sam Ackroyd, Joanne Ewing, Pratap Neelakantan, Mamta Garg, David Tucker, John Murphy, Hitesh Patel, Rozinder Bains, Gavin Chiu, Joe Hickey, Claire Harrison and Tim C. P. Somervaille in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

5. sj-docx-3-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Author

Mead, Adam J., Butt, Nauman M., Nagi, Waseem, Whiteway, Alastair, Kirkpatrick, Suriya, Rinaldi, Ciro, Roughley, Catherine, Ackroyd, Sam, Ewing, Joanne, Neelakantan, Pratap, Garg, Mamta, Tucker, David, Murphy, John, Patel, Hitesh, Bains, Rozinder, Chiu, Gavin, Hickey, Joe, Harrison, Claire, and Somervaille, Tim C. P.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-3-tah-10.1177_20406207221084487 for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study by Adam J. Mead, Nauman M. Butt, Waseem Nagi, Alastair Whiteway, Suriya Kirkpatrick, Ciro Rinaldi, Catherine Roughley, Sam Ackroyd, Joanne Ewing, Pratap Neelakantan, Mamta Garg, David Tucker, John Murphy, Hitesh Patel, Rozinder Bains, Gavin Chiu, Joe Hickey, Claire Harrison and Tim C. P. Somervaille in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

6. sj-docx-1-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Author

Mead, Adam J., Butt, Nauman M., Nagi, Waseem, Whiteway, Alastair, Kirkpatrick, Suriya, Rinaldi, Ciro, Roughley, Catherine, Ackroyd, Sam, Ewing, Joanne, Neelakantan, Pratap, Garg, Mamta, Tucker, David, Murphy, John, Patel, Hitesh, Bains, Rozinder, Chiu, Gavin, Hickey, Joe, Harrison, Claire, and Somervaille, Tim C. P.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tah-10.1177_20406207221084487 for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study by Adam J. Mead, Nauman M. Butt, Waseem Nagi, Alastair Whiteway, Suriya Kirkpatrick, Ciro Rinaldi, Catherine Roughley, Sam Ackroyd, Joanne Ewing, Pratap Neelakantan, Mamta Garg, David Tucker, John Murphy, Hitesh Patel, Rozinder Bains, Gavin Chiu, Joe Hickey, Claire Harrison and Tim C. P. Somervaille in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

7. sj-docx-4-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Author

Mead, Adam J., Butt, Nauman M., Nagi, Waseem, Whiteway, Alastair, Kirkpatrick, Suriya, Rinaldi, Ciro, Roughley, Catherine, Ackroyd, Sam, Ewing, Joanne, Neelakantan, Pratap, Garg, Mamta, Tucker, David, Murphy, John, Patel, Hitesh, Bains, Rozinder, Chiu, Gavin, Hickey, Joe, Harrison, Claire, and Somervaille, Tim C. P.

Subjects
FOS: Clinical medicine, Cardiology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-4-tah-10.1177_20406207221084487 for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study by Adam J. Mead, Nauman M. Butt, Waseem Nagi, Alastair Whiteway, Suriya Kirkpatrick, Ciro Rinaldi, Catherine Roughley, Sam Ackroyd, Joanne Ewing, Pratap Neelakantan, Mamta Garg, David Tucker, John Murphy, Hitesh Patel, Rozinder Bains, Gavin Chiu, Joe Hickey, Claire Harrison and Tim C. P. Somervaille in Therapeutic Advances in Hematology

Published
2022
Full Text
View/download PDF

8. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Author

Mead, Adam J., primary, Butt, Nauman M., additional, Nagi, Waseem, additional, Whiteway, Alastair, additional, Kirkpatrick, Suriya, additional, Rinaldi, Ciro, additional, Roughley, Catherine, additional, Ackroyd, Sam, additional, Ewing, Joanne, additional, Neelakantan, Pratap, additional, Garg, Mamta, additional, Tucker, David, additional, Murphy, John, additional, Patel, Hitesh, additional, Bains, Rozinder, additional, Chiu, Gavin, additional, Hickey, Joe, additional, Harrison, Claire, additional, and Somervaille, Tim C. P., additional

Published
2022
Full Text
View/download PDF

9. Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

Author

Loke, (Justin) Ching Ting, primary, Gaskell, Charlotte, additional, Fox, Sonia, additional, Fletcher, Rachel, additional, Thomas, Catherine, additional, Hopkins, Louise, additional, Kumari, Anita, additional, Boucher, Rebecca H., additional, Nunnick, Jane, additional, Knapper, Steve, additional, Toth, Arpad, additional, Byrne, Jennifer, additional, O'Nions, Jenny, additional, Khan, Anjum, additional, Zhao, Rui, additional, Pillai, Arvind, additional, Tholouli, Eleni, additional, Dungarwalla, Moez, additional, Randall, Katie, additional, Dillon, Richard, additional, Murray, Duncan, additional, Culligan, Dominic, additional, McMullin, Mary Frances, additional, Chan, Yuen Ling Tracey, additional, Drew, Victoria, additional, Murthy, Vidhya, additional, Krishnamurthy, Pramila, additional, Neelakantan, Pratap, additional, Rider, Tom, additional, Wandroo, Farooq A, additional, Rafferty, Mark, additional, Huang, Ya-Wen, additional, Moore, Sally, additional, Mehta, Priyanka, additional, Partridge, David G, additional, Craddock, Charles, additional, Lowe, David, additional, and Stanworth, Simon J., additional

Published
2021
Full Text
View/download PDF

11. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy

Author

Booth, Stephen, primary, Willan, John, additional, Wong, Henna, additional, Khan, Dalia, additional, Farnell, Rachel, additional, Hunter, Alicia, additional, Eyre, Toby, additional, Katz, Harley, additional, Dungarwalla, Moez, additional, Chen, Lucia, additional, Browning, Joe, additional, Polzella, Paolo, additional, Gray, Nicola, additional, Neelakantan, Pratap, additional, Dhillon, Elissa K., additional, Dutton, David, additional, Sternberg, Alex, additional, Prideaux, Steven, additional, Collins, Graham P., additional, and Peniket, Andy, additional

Published
2020
Full Text
View/download PDF

12. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Author

Milojkovic, Dragana, primary, Cross, Nicholas C. P., additional, Ali, Sahra, additional, Byrne, Jenny, additional, Campbell, Gavin, additional, Dignan, Fiona L., additional, Drummond, Mark, additional, Huntly, Brian, additional, Marshall, Scott, additional, McMullin, Mary Frances, additional, Neelakantan, Pratap, additional, Raghavan, Manoj, additional, Sivakumaran, Muttuswamy, additional, Tighe, Jane, additional, Wandroo, Farooq, additional, Willis, Fenella, additional, Glen, Fiona, additional, Fildes, Louise, additional, Collington, Sarah J., additional, Ryan, Jacqueline, additional, Clark, Richard E., additional, and Mead, Adam J., additional

Published
2020
Full Text
View/download PDF

14. A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

Author

Mead, Adam J., primary, Somervaille, Tim, additional, Butt, Nauman M, additional, Nagi, Waseem, additional, Whiteway, Alastair J, additional, Kirkpatrick, Suriya, additional, Rinaldi, Ciro R, additional, Roughley, Catherine, additional, Ackroyd, Sam, additional, Ewing, Joanne, additional, Neelakantan, Pratap, additional, Garg, Mamta, additional, Harrison, Claire N, additional, Tucker, David, additional, Bains, Rozinder, additional, Chiu, Gavin, additional, and Hickey, Joe, additional

Published
2019
Full Text
View/download PDF

15. Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Author

Byrne, Jenny, primary, Ewing, Joanne, additional, Mead, Adam J., additional, Oakervee, Heather, additional, Campbell, Gavin, additional, Amott, Ian, additional, Goringe, Andrew, additional, Heartin, Earnest, additional, Dimitriadou, Evangelia, additional, Pamphlett, Ian, additional, Arami, Siamak, additional, Neelakantan, Pratap, additional, Frewin, Rebecca, additional, Pillai, Srinivas, additional, De Lavallade, Hugues, additional, Cross, Nicholas C.P., additional, and Thompson, Michael, additional

Published
2019
Full Text
View/download PDF

17. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.

Author

Milojkovic, Dragana, Cross, Nicholas C. P., Ali, Sahra, Byrne, Jenny, Campbell, Gavin, Dignan, Fiona L., Drummond, Mark, Huntly, Brian, Marshall, Scott, McMullin, Mary Frances, Neelakantan, Pratap, Raghavan, Manoj, Sivakumaran, Muttuswamy, Tighe, Jane, Wandroo, Farooq, Willis, Fenella, Glen, Fiona, Fildes, Louise, Collington, Sarah J., and Ryan, Jacqueline

Subjects
PROTEIN-tyrosine kinase inhibitors, CHRONIC myeloid leukemia, CARDIOVASCULAR diseases risk factors, NILOTINIB, PATIENT care
Abstract

Summary: Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real‐world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic‐phase CML who had been prescribed a first‐line TKI between 2013 and 2017, most of whom received first‐line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real‐world data revealed that molecular assessments were frequently missed, 23% of patients with ELN‐defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR‐ABL1IS ≤0·1%) and deep molecular response (DMR; BCR‐ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first‐line imatinib, and 63% and 54%, respectively, receiving a second‐generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow‐up, receiving a second‐generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.

Author

Djebbari, Faouzi, Hubenov, Huben, Neelakantan, Pratap, Wolf, Julia, Offer, Mark, Khera, Akhil, Louka, Eleni, Vallance, Grant, Kothari, Jaimal, Moore, Sally, and Ramasamy, Karthik

Subjects
BUNDLE-branch block, LEFT ventricular hypertrophy, STEM cell transplantation, PATIENT selection
Abstract

Twenty-nine patients (97%) received at least two cycles of therapy and one patient discontinued carfilzomib after one cycle. Carfilzomib therapy is ongoing in 17 patients and was discontinued in 13 patients. Five patients received full twice-weekly dosing throughout therapy, and six patients were dose-reduced to weekly upfront (i.e. from cycle 1). Depending on the severity of hypertension, management consisted of introducing an antihypertensive (e.g., amlodipine) in two patients, an antihypertensive dose increase in two patients, carfilzomib dose reduction in two patients, and an antihypertensive plus carfilzomib dose reduction in one patient. [Extracted from the article]

Published
2020
Full Text
View/download PDF

20. The management of myelofibrosis: A British Society for Haematology Guideline.

Author

McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, Butt NM, Cargo C, Cross NCP, Francis S, Frewin R, Garg M, Godfrey AL, Green A, Khan A, Knapper S, Lambert J, McGregor A, McMullin MF, Nangalia J, Neelakantan P, Woodley C, Mead A, Somervaille TCP, and Harrison CN

Subjects
Humans, Primary Myelofibrosis diagnosis, Primary Myelofibrosis therapy, Hematology, Hematopoietic Stem Cell Transplantation
Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results